194 related articles for article (PubMed ID: 22373583)
21. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract][Full Text] [Related]
22. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
24. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
25. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
26. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
27. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
30. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
31. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
32. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
33. Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer.
Zeng Q; Liu M; Zhou N; Liu L; Song X
Clin Chim Acta; 2016 Apr; 455():102-6. PubMed ID: 26851650
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
[TBL] [Abstract][Full Text] [Related]
35. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Mi D; Zhang Y
Arch Gynecol Obstet; 2020 Mar; 301(3):779-785. PubMed ID: 32034508
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
38. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
39. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis.
Wu L; Dai ZY; Qian YH; Shi Y; Liu FJ; Yang C
Int J Gynecol Cancer; 2012 Sep; 22(7):1106-12. PubMed ID: 22854652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
